Literature DB >> 21428405

Chemistry and biology of macrolide antiparasitic agents.

Younjoo Lee1, Jun Yong Choi, Hong Fu, Colin Harvey, Sandeep Ravindran, William R Roush, John C Boothroyd, Chaitan Khosla.   

Abstract

Macrolide antibacterial agents inhibit parasite proliferation by targeting the apicoplast ribosome. Motivated by the long-term goal of identifying antiparasitic macrolides that lack antibacterial activity, we have systematically analyzed the structure-activity relationships among erythromycin analogues and have also investigated the mechanism of action of selected compounds. Two lead compounds, N-benzylazithromycin (11) and N-phenylpropylazithromycin (30), were identified with significantly higher antiparasitic activity and lower antibacterial activity than erythromycin or azithromycin. Molecular modeling based on the cocrystal structure of azithromycin bound to the bacterial ribosome suggested that a substituent at the N-9 position of desmethylazithromycin could improve selectivity because of species-specific interactions with the ribosomal L22 protein. Like other macrolides, these lead compounds display a strong "delayed death phenotype"; however, their early effects on T. gondii replication are more pronounced.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21428405      PMCID: PMC3085955          DOI: 10.1021/jm101593u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

1.  The complete atomic structure of the large ribosomal subunit at 2.4 A resolution.

Authors:  N Ban; P Nissen; J Hansen; P B Moore; T A Steitz
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

2.  High resolution structure of the large ribosomal subunit from a mesophilic eubacterium.

Authors:  J Harms; F Schluenzen; R Zarivach; A Bashan; S Gat; I Agmon; H Bartels; F Franceschi; A Yonath
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 3.  Ribosomal antibiotics: structural basis for resistance, synergism and selectivity.

Authors:  Tamar Auerbach; Anat Bashan; Ada Yonath
Journal:  Trends Biotechnol       Date:  2004-11       Impact factor: 19.536

Review 4.  Effectiveness of antimalarial drugs.

Authors:  J Kevin Baird
Journal:  N Engl J Med       Date:  2005-04-14       Impact factor: 91.245

5.  In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.

Authors:  M E Fichera; M K Bhopale; D S Roos
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

6.  Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA.

Authors:  S T Gregory; A E Dahlberg
Journal:  J Mol Biol       Date:  1999-06-18       Impact factor: 5.469

7.  Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro.

Authors:  Michael Millrose; Matthias Kruse; Burkhard Flick; Ralf Stahlmann
Journal:  Arch Toxicol       Date:  2008-12-04       Impact factor: 5.153

Review 8.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

9.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

Review 10.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more
  9 in total

1.  Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.

Authors:  Arren Z Washington; Subhasish Tapadar; Alex George; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2015-05-06       Impact factor: 3.641

Review 2.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Ketolide agents HMR 3004 and HMR 3647 (telithromycin) inhibit the growth of Plasmodium falciparum in vitro.

Authors:  Marema Makgatho; Eric Maimela; Felix Mbajiorgu
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

4.  Chemobiosynthesis of new antimalarial macrolides.

Authors:  Christopher D Goodman; Mariana Useglio; Salvador Peirú; Guillermo R Labadie; Geoffrey I McFadden; Eduardo Rodríguez; Hugo Gramajo
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

5.  A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.

Authors:  Subhasish Tapadar; Shaghayegh Fathi; Idris Raji; Wilson Omesiete; James R Kornacki; Sandra C Mwakwari; Masanori Miyata; Kazunori Mitsutake; Jian-Dong Li; Milan Mrksich; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2015-11-02       Impact factor: 3.641

Review 6.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

7.  Synthesis and Antibacterial Evaluation of a Series of 11,12-Cyclic Carbonate Azithromycin-3-O-descladinosyl-3-O-carbamoyl Glycosyl Derivatives.

Authors:  Chao-Ming Wang; Feng-Lan Zhao; Lei Zhang; Xiao-Yun Chai; Qing-Guo Meng
Journal:  Molecules       Date:  2017-12-04       Impact factor: 4.411

Review 8.  Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development.

Authors:  Takuro Endo; Hitoshi Takemae; Indu Sharma; Tetsuya Furuya
Journal:  Front Cell Infect Microbiol       Date:  2021-12-24       Impact factor: 5.293

9.  Retargeting azithromycin analogues to have dual-modality antimalarial activity.

Authors:  Amy L Burns; Brad E Sleebs; Ghizal Siddiqui; Amanda E De Paoli; Dovile Anderson; Benjamin Liffner; Richard Harvey; James G Beeson; Darren J Creek; Christopher D Goodman; Geoffrey I McFadden; Danny W Wilson
Journal:  BMC Biol       Date:  2020-09-29       Impact factor: 7.431

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.